Becton, Dickinson and Company (NYSE:BDX) Forecasted to Earn Q2 2023 Earnings of $2.81 Per Share

Becton, Dickinson and Company (NYSE:BDXGet Rating) – Analysts at KeyCorp issued their Q2 2023 earnings per share (EPS) estimates for shares of Becton, Dickinson and in a report released on Thursday, November 10th. KeyCorp analyst M. Mishan anticipates that the medical instruments supplier will post earnings per share of $2.81 for the quarter. The consensus estimate for Becton, Dickinson and’s current full-year earnings is $12.02 per share. KeyCorp also issued estimates for Becton, Dickinson and’s Q3 2023 earnings at $3.14 EPS, Q4 2023 earnings at $3.38 EPS, FY2023 earnings at $11.90 EPS and FY2024 earnings at $13.41 EPS.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.01. The business had revenue of $4.76 billion during the quarter, compared to analyst estimates of $4.72 billion. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.56%. Becton, Dickinson and’s revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.15 earnings per share.

Several other equities research analysts have also issued reports on the company. Morgan Stanley lifted their price target on Becton, Dickinson and from $272.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 11th. StockNews.com lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup decreased their price target on shares of Becton, Dickinson and from $235.00 to $227.00 in a research note on Wednesday, October 5th. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research note on Monday, July 18th. Finally, The Goldman Sachs Group lifted their target price on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $275.75.

Becton, Dickinson and Stock Down 0.7 %

Shares of NYSE:BDX opened at $227.67 on Monday. The firm has a market capitalization of $64.93 billion, a PE ratio of 38.72, a price-to-earnings-growth ratio of 2.45 and a beta of 0.61. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35. Becton, Dickinson and has a 52-week low of $215.90 and a 52-week high of $280.62. The firm has a fifty day moving average of $234.58 and a 200 day moving average of $244.44.

Hedge Funds Weigh In On Becton, Dickinson and

Hedge funds and other institutional investors have recently modified their holdings of the company. Western Pacific Wealth Management LP purchased a new stake in Becton, Dickinson and in the 3rd quarter worth approximately $30,000. Core Alternative Capital lifted its stake in Becton, Dickinson and by 688.2% in the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 117 shares during the period. SJS Investment Consulting Inc. bought a new stake in Becton, Dickinson and in the third quarter valued at $36,000. McIlrath & Eck LLC increased its position in Becton, Dickinson and by 44.9% during the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 44 shares during the period. Finally, Chilton Capital Management LLC bought a new position in Becton, Dickinson and in the 2nd quarter worth $39,000. 86.74% of the stock is owned by institutional investors.

Becton, Dickinson and Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 9th will be issued a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a yield of 1.60%. The ex-dividend date of this dividend is Thursday, December 8th. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.87. Becton, Dickinson and’s dividend payout ratio (DPR) is 59.18%.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.